Sildenafil Formulations: Oral and Injectable Forms Explained

Sildenafil Formulations at a Glance

Sildenafil dosage forms differ in physical presentation, route of administration and regulatory product context. Oral products now include conventional tablets, oral film and suspension, while REVATIO also has an intravenous formulation.

The active drug remains sildenafil, but dosage form alone does not establish indication. Tablets can belong to ED or PAH products, VYBRIQUE oral film belongs to an ED framework, and the major U.S. suspension and injection contexts are associated with PAH.

The oral-suspension category also contains more than one pharmaceutical presentation. Some products are supplied as powder that must be reconstituted before use, while LIQREV is supplied as an oral suspension rather than as powder for reconstitution.

What Is a Sildenafil Formulation?

In pharmaceutical use, formulation refers broadly to how an active drug is prepared together with inactive ingredients and presented as a finished medicine. Dosage form is the physical presentation of that formulation, such as a tablet, film, suspension or injectable solution.

Route is a separate concept describing how the medicine is administered. A tablet, oral film and oral suspension all use an oral route despite being different dosage forms, while sildenafil injection uses an intravenous route.

Keeping active ingredient, salt form, formulation, dosage form, route and brand separate prevents several common errors when comparing sildenafil products.

Sildenafil Tablets

Tablets remain the most established sildenafil dosage form and appear in more than one clinical indication. ED-oriented sildenafil tablets commonly include 25 mg, 50 mg and 100 mg strengths, while REVATIO and PAH-oriented generic tablets use a 20 mg product framework.

Because both groups are tablets containing sildenafil, physical dosage form alone cannot identify the approved indication. The relevant product, strength and prescribing information must also be known.

Generic sildenafil tablets can also have different manufacturers and inactive ingredients while remaining within their applicable regulatory reference framework. The dedicated sildenafil tablets guide covers the solid oral form in greater detail.

Sildenafil Oral Film

Oral film became an important additional sildenafil dosage-form category with FDA approval of VYBRIQUE in December 2025. VYBRIQUE is a sildenafil oral film indicated for erectile dysfunction.

Current labeling describes thin, flexible oral films containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil. The film is placed on the tongue, where it disintegrates before being swallowed with saliva without requiring water.

Oral film shares the oral route with tablets but is not simply a tablet in different packaging. Its physical formulation, administration instructions, strength set and food-effect profile are product-specific.

Sildenafil Oral Suspension

Sildenafil liquid products require a more precise distinction than simply calling all of them 'oral suspension.' REVATIO is supplied as powder for oral suspension that must be reconstituted with water before use, producing a final sildenafil concentration of 10 mg/mL.

Generic sildenafil products also exist as powder for oral suspension within applicable PAH regulatory contexts. These products follow the same basic reconstitution concept: a dry pharmaceutical preparation becomes a suspension only after the specified amount of water is added.

LIQREV represents a different pharmaceutical presentation. It was FDA-approved as a sildenafil oral suspension containing 10 mg/mL and is supplied as the liquid suspension itself rather than as REVATIO-style powder requiring reconstitution. The dedicated sildenafil oral suspension guide covers these distinctions in depth.

Sildenafil Injection

Sildenafil injection is an intravenous dosage form belonging to the PAH product framework. Current REVATIO labeling includes a clear, colorless sterile solution supplied in a single-dose vial containing 10 mg sildenafil in 12.5 mL.

Intravenous administration bypasses gastrointestinal absorption and oral bioavailability, making its pharmacokinetic input fundamentally different from tablets, film or suspension.

REVATIO injection should not be interpreted as an alternative erectile-dysfunction formulation. Its route, labeling and clinical use are tied to the PAH context. The dedicated sildenafil injection guide covers this formulation separately.

Same Active Ingredient Does Not Mean Same Formulation

Tablets, oral film, suspension and injection can all deliver sildenafil, but active-drug identity is only one layer of product information. Their excipients, physical structure, route, handling and product-specific labeling can differ.

Those differences can have practical pharmacokinetic consequences. Oral dosage forms require gastrointestinal administration, while intravenous sildenafil bypasses oral absorption; food effects can also differ between tablets and oral film.

Sharing sildenafil therefore does not establish pharmaceutical equivalence or clinical interchangeability across formulations.

How Sildenafil Brands Relate to Formulations

A brand identifies a particular drug product, while dosage form identifies its physical pharmaceutical presentation. One brand can contain several dosage forms, and one active drug can appear under several brands.

REVATIO is the clearest multi-form example because its labeling combines tablets, powder for oral suspension and injection. Viagra is a tablet product, VYBRIQUE is an oral-film product and LIQREV is an oral-suspension product.

This product-form relationship is increasingly important because modern sildenafil can no longer be mapped accurately using only the older Viagra-versus-Revatio distinction. The broader brand landscape is covered on the sildenafil brand names page.

Formulation vs Route of Administration

Route of administration describes how sildenafil enters the body, whereas dosage form describes the physical medicine used to deliver it. Multiple dosage forms can therefore share one route.

Tablets, oral film and oral suspension all use the oral route despite having very different physical presentations. REVATIO injection uses an intravenous route and bypasses the gastrointestinal absorption process.

Keeping route separate from dosage form is particularly useful when comparing pharmacokinetics because route determines whether oral absorption and first-pass availability contribute to systemic input.

Why Each Sildenafil Formulation Has Its Own Regulatory Context

FDA approval is attached to specific drug applications and finished products rather than to sildenafil in every possible pharmaceutical form. A new dosage form can therefore require a separate NDA or another applicable regulatory pathway.

This is visible throughout sildenafil's regulatory history: Viagra established the original tablet milestone; REVATIO later added its PAH tablet, injection and powder-for-suspension products; LIQREV received a separate 505(b)(2) NDA for oral suspension; and VYBRIQUE received a separate 505(b)(2) NDA for oral film.

Generic versions use their own abbreviated regulatory pathway tied to an appropriate reference product. The chronology and application numbers are covered on the sildenafil FDA approval page.

Why Sildenafil Formulations Are Not Automatically Interchangeable

The fact that two products contain sildenafil does not mean one can automatically replace the other. Pharmaceutical equivalence and therapeutic-equivalence determinations operate within defined regulatory relationships rather than across every sildenafil dosage form.

A 20 mg PAH tablet, an ED oral film, a reconstituted suspension and an intravenous solution differ in more than appearance. They can belong to different indications, strengths, routes and approved administration frameworks.

Even two oral liquid products require attention to pharmaceutical presentation: powder that must be reconstituted and a finished suspension are not identical formulations merely because both ultimately contain sildenafil at 10 mg/mL.

Tablet vs Oral Suspension: Key Difference

Tablet and oral-suspension sildenafil share an oral administration route but differ substantially in pharmaceutical preparation. A tablet is a discrete solid dosage unit, whereas suspension provides sildenafil particles dispersed in a liquid vehicle.

The suspension category itself requires another distinction: REVATIO-type products begin as powder and require reconstitution, whereas LIQREV is supplied as an oral suspension.

These formulation differences affect handling, measurement, storage and product instructions without changing the identity of sildenafil as the active drug. The detailed comparison belongs on the sildenafil tablets vs oral suspension page.

Oral vs Injectable Sildenafil

Oral sildenafil formulations include tablets, oral film and oral suspension. All require oral administration, whereas sildenafil injection delivers the drug intravenously.

That route difference changes systemic input. Oral products are affected by gastrointestinal absorption and bioavailability, while intravenous administration bypasses those processes.

REVATIO injection belongs to the PAH framework and should not be interpreted as an injectable alternative to ED tablets or oral film. The dedicated oral vs injectable sildenafil comparison explains the route and regulatory differences in greater depth.

Common Sildenafil Formulation Terms

Sildenafil product descriptions often combine several regulatory and pharmaceutical terms that refer to different layers of the medicine.

The distinction is increasingly important now that sildenafil is marketed or approved across tablets, oral film, reconstituted suspension, finished oral suspension and injection. Using 'formulation' as though it meant brand, strength or indication can create inaccurate comparisons.

How to Navigate Sildenafil Formulation Information

This page serves as the central dosage-form map. Individual pages then separate the pharmaceutical questions that require more detail, including solid tablets, liquid suspension, intravenous sildenafil and direct route or formulation comparisons.

The correct destination depends on whether the reader wants to understand the physical dosage form, compare two formulations, examine brand relationships or review the FDA approval history.

There is currently no separate oral-film URL in this site structure, so VYBRIQUE oral film is covered here as part of the formulation overview rather than linked to a nonexistent page.